Dizaltı femoropopliteal bypass girişimlerimiz

Amaç: Bu çalışmada dizaltı femoropopliteal bypass ameliyatı uygulanan hastalarda tedavi sonuçları değerlendirildi. Çalışma planı: Çalışmada 37 hasta (30 erkek, 7 kadın; ort. yaş 61; dağılım 21-82) geriye dönük olarak değerlendirildi. Hastaların klinik durumları ve greft açıklıkları belirlendi.Bulgular: Distal anastomoz 28 hastada (%75.7) popliteal arterde trifurkasyon düzeyine, bir hastada (%2.7) tibioperoneal trunka, dört hastada (%10.8) tibialis posteriora, dört hastada ise tibialis anteriora yapıldı. Hastaların 28'inde otojen revers safen ven kullanılırken, dokuz hastada politetrafloroetilen greftler tercih edildi. Sentetik greft takılan tüm olgulara antikoagülan tedavi uygulandı. Hiçbir olguda mortalite görülmedi. Yedi hastaya (%18.9) greft yetmezliği nedeniyle trombektomi uygulandı. Bir yıllık açık kalma oranları otojen safen ven greftinde %89.3, sentetik greftlerde %55.6 (p

Infrainguinal femoropopliteal bypass operations

Background: We evaluated the results of infrainguinal femoropopliteal bypass operations. Methods: Thirty-seven patients (30 males, 7 females; mean age 61 years; range 21 to 82 years) were retrospectively evaluated. Clinical results and graft patencies were determined.Results: Distal anastomoses were placed at the level of popliteal artery trifurcation in 28 patients (75.7%), to the tibioperoneal trunk in one patient (2.7%), posterior tibial artery in four patients (10.8%), and anterior tibial artery in four patients. Reversed autogenous saphenous vein was used in 28 patients and polytetrafluoroethylene graft was used in nine patients. All patients receiving a synthetic graft were treated with anticoagulants. Mortality did not occur. Thrombectomy was performed in seven patients (18.9%) due to graft failure. One-year patency rate was 89.3% with autogenous saphenous veins, and 55.6% with synthetic grafts (p

PDF

___

1) Kurç E, Enç Y, Çınar B, Kurç P, Kösem M, Sezerman Ö. Femoropopliteal bypass cerrahisinde greft seçimimiz ve uzun dönem patency sonuçlarımız. Türk Göğüs Kalp Damar Cer Derg 200;8:616-8.
2) Veith FJ, Haimovici H. Femoropopliteal arteriosclerotic occlusive disease: In: Haimovici H, editor. Haimovici’s vascular sugery. 4th ed. Cambridge: Blackwell Science; 1996. p. 605-31.
3) Edwards WH, Mulherin JL Jr. The role of graft material in femorotibial bypass grafts. Ann Surg 1980;191:721-6.
4) Klinkert P, Post PN, Breslau PJ, van Bockel JH. Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of the literature. Eur J Vasc Endovasc Surg 2004; 27:357-62.
5) Falco E, Celoria G, Nardini A, Saccomanno G, De Franchi G, Zappia F, et al. Femoro-popliteal bypass with reversed saphenous vein. Experience in a General Surgery Department. Minerva Chir 1995;50:883-8. [Abstract]
6) Plecha EJ, Freischlag JA, Seabrook GR, Towne JB. Femoropopliteal bypass revisited: an analysis of 138 cases. Cardiovasc Surg 1996;4:195-9.
7) Towne JB. The autogenous vein. In: Rutherford RB, editor. Vascular surgery. 4th ed. Philadelphia: W. B. Saunders; 1995. p. 482-91.
8) Hall KV. The great saphenous vein used in situ as an arterial shunt after extirpation of the vein valves. A preliminary report. Surgery 1962;51:492-5.
9) Lawson JA, Tangelder MJ, Algra A, Eikelboom BC. The myth of the in situ graft: superiority in infrainguinal bypass surgery? Eur J Vasc Endovasc Surg 1999;18:149-57.
10) Wengerter KR, Veith FJ, Gupta SK, Goldsmith J, Farrell E, Harris PL, et al. Prospective randomized multicenter comparison of in situ and reversed vein infrapopliteal bypasses. J Vasc Surg 1991;13:189-97.
11) Abbott WM. Prosthetic above-knee femoral-popliteal bypass: indications and choice of graft. Semin Vasc Surg 1997;10:3-7.
12) Prendiville EJ, Yeager A, O’Donnell TF Jr, Coleman JC, Jaworek A, Callow AD, et al. Long-term results with the above-knee popliteal expanded polytetrafluoroethylene graft. J Vasc Surg 1990;11:517-24.
13) Klinkert P, Schepers A, Burger DH, van Bockel JH, Breslau PJ. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: five year results of a randomized controlled trial. J Vasc Surg 2003;37:149-55.
14) Albers M, Battistella VM, Romiti M, Rodrigues AA, Pereira CA. Meta-analysis of polytetrafluoroethylene bypass grafts to infrapopliteal arteries. J Vasc Surg 2003;37:1263-9.
15) Post S, Kraus T, Muller-Reinartz U, Weiss C, Kortmann H, Quentmeier A, et al. Dacron vs. polytetrafluoroethylene grafts for femoropopliteal bypass: a prospective randomised multicentre trial. Eur J Vasc Endovasc Surg 2001;22:226 31.
16) Lin PH, Bush RL, Yao Q, Lumsden AB, Chen C. Evaluation of platelet deposition and neointimal hyperplasia of heparincoated small-caliber ePTFE grafts in a canine femoral artery bypass model. J Surg Res 2004;118:45-52.
17) Bosiers M, Deloose K, Verbist J, Schroe H, Lauwers G, Lansink W, et al. Heparin-bonded expanded polytetrafluoroethylene vascular graft for femoropopliteal and femorocrural bypass grafting: 1-year results. J Vasc Surg 2006; 43:313-8.
18) Devine C, McCollum C; North West Femoro-Popliteal Trial Participants. Heparin-bonded Dacron or polytetrafluoroethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial. J Vasc Surg 2004;40:924-31.
19) Woodburn KR, Rumley A, Lowe GD, Love JG, Murray GD, Pollock JG. Clinical, biochemical, and rheologic factors affecting the outcome of infrainguinal bypass grafting. J Vasc Surg 1996;24:639-46.
20) Desai TR, Meyerson SL, Skelly CL, MacKenzie KS, Bassiouny HS, Katz D, et al. Patency and limb salvage after infrainguinal bypass with severely compromised (“blind”) outflow. Arch Surg 2001;136:635-42.
21) Blankensteijn JD, Gertler JP, Brewster DC, Cambria RP, LaMuraglia GM, Abbott WM. Intraoperative determinants of infrainguinal bypass graft patency: a prospective study. Eur J Vasc Endovasc Surg 1995;9:375-82.
22) Alback A, Biancari F, Saarinen O, Lepantalo M. Prediction of the immediate outcome of femoropopliteal saphenous vein bypass by angiographic runoff score. Eur J Vasc Endovasc Surg 1998;15:220-4.
23) Diehm N, Shang A, Silvestro A, Do DD, Dick F, Schmidli J, et al. Association of cardiovascular risk factors with pattern of lower limb atherosclerosis in 2659 patients undergoing angioplasty. Eur J Vasc Endovasc Surg 2006;31:59-63.
24) Seeger JM, Pretus HA, Carlton LC, Flynn TC, Ozaki CK, Huber TS. Potential predictors of outcome in patients with tissue loss who undergo infrainguinal vein bypass grafting. J Vasc Surg 1999;30:427-35.
25) Donaldson MC, Weinberg DS, Belkin M, Whittemore AD, Mannick JA. Screening for hypercoagulable states in vascular surgical practice: a preliminary study. J Vasc Surg 1990; 11:825-31.
26) Vallus G, Dlustus B, Acsady G, Papp Z, Skopal J, Nagy Z, et al. Factor V Leiden and apolipoprotein E genotypes in severe femoropopliteal atherosclerosis with restenosis. Clin Chim Acta 2007;377:256-60.
27) Curi MA, Skelly CL, Baldwin ZK, Woo DH, Baron JM, Desai TR, et al. Long term outcome of infrainguinal bypass grafting in patients with serologically proven hypercoagulability. J Vasc Surg 2003;37:301-6.
28) Kraiss LW, Johansen K. Pharmacologic intervention to prevent graft failure. Surg Clin North Am 1995;75:761-72.
29) Kretschmer G, Herbst F, Prager M, Sautner T, Wenzl E, Berlakovich GA, et al. A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch Surg 1992;127:1112-5.
30) Sarac TP, Huber TS, Back MR, Ozaki CK, Carlton LM, Flynn TC, et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 1998;28:446-57.